Australians want cheaper medicines quicker

20 May 2019 - Just last week, an 18-year-old woman with a rare cancer was staring down the barrel of ...

Read more →

NICE recommends Revlimid as multiple myeloma alternative

17 May 2019 - NICE has recommended Revlimid (lenalidomide), a drug that helps to support the immune system to fight ...

Read more →

Celgene receives European Commission approvals for Revlimid (lenalidomide) and Imnovid (pomalidomide)-based triplet combination regimens for patients with multiple myeloma

16 May 2019 - The European Commission has approved two of Celgene’s IMiD based combination regimens. ...

Read more →

Health technology assessment challenges in oncology: 20 years of Value in Health

16 May 2019 - Oncology treatments have changed from chemotherapies to targeted therapies and more recently immuno-oncology.  ...

Read more →

Nivolumab and ipilimumab: drug combination has added benefit in advanced renal cell carcinoma

15 May 2019 - There are no serious disadvantages in terms of overall survival. ...

Read more →

Novartis gets approval to sell Kymriah in Japan for $306,000

15 May 2019 - A Japanese government panel approved on Wednesday a price of 33.5 million yen ($305,800) for Novartis’ cancer ...

Read more →

AbbVie announces US FDA approval of Venclexta (venetoclax) as a chemotherapy-free combination regimen for previously untreated chronic lymphocytic leukaemia patients

15 May 2019 - FDA reviewed the submission under the real-time oncology review pilot program. ...

Read more →

FDA approves Bavencio (avelumab) plus axitinib combination for patients with advanced renal cell carcinoma

14 May 2019 - Phase III study showed combination significantly lowered risk of disease progression or death by 31% and extended ...

Read more →

Cellectar receives FDA fast track designation for CLR 131 in relapsed or refractory multiple myeloma

13 May 2019 - Designation could accelerate CLR 131 development and underscores the need for new treatments. ...

Read more →

Celgene Corporation announces Pomalyst granted breakthrough therapy designation from FDA for HIV positive and negative Kaposi sarcoma

13 May 2019 - Celgene plans to submit sNDA by end of 2019. ...

Read more →

Japan health ministry orders Ono Pharmaceutical to add warning to Opdivo cancer drug after death

10 May 2019 - The health ministry said Thursday that a patient taking the cancer drug Opdivo has died and ...

Read more →

New cancer drugs approved for NHS use in Scotland

13 May 2019 - The Scottish Medicines Consortium accepted the use of new medicines to treat patients with breast and skin ...

Read more →

Lilly's Cyramza (ramucirumab) becomes first FDA approved biomarker-driven therapy in patients with hepatocellular carcinoma

13 May 2019 - This new indication - the fifth FDA approval for Cyramza in an advanced or metastatic cancer - ...

Read more →

Speed up cancer funding, ALP told

11 May 2019 - The head of Australian drug company Specialised Therapeutics, Carlo Montagner, has warned that Bill Shorten’s cancer ...

Read more →

Cancer specialists ‘won’t increase’ fees under Labor plan

9 May 2019 - Australia’s cancer doctors have rejected Scott Morrison’s claims they will charge patients higher fees under Labor’s ...

Read more →